NFKB1 and brain cancer: SN50, a cell-permeable peptide inhibitor of NF-κB, results in decreased oncogenesis and induced differentiation of human glioma stem-like cells, suggesting that blocking the NF-κB signaling pathway is a potential therapeutic strategy for treating malignant brain tumors [124].